Editas Medicine, Inc.
EDIT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $8 | $4 | $5 | $31 |
| % Growth | 110.8% | -23.2% | -84.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $8 | $4 | $5 | $31 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $20 | $16 | $27 | $49 |
| G&A Expenses | $12 | $13 | $13 | $16 |
| SG&A Expenses | $12 | $13 | $13 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $26 | $41 | $12 |
| Operating Expenses | $32 | $55 | $81 | $77 |
| Operating Income | -$25 | -$52 | -$76 | -$47 |
| % Margin | -325.4% | -1,440.6% | -1,635.1% | -152.2% |
| Other Income/Exp. Net | -$1 | -$2 | $0 | $1 |
| Pre-Tax Income | -$25 | -$53 | -$76 | -$45 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25 | -$53 | -$76 | -$45 |
| % Margin | -333% | -1,487.8% | -1,633.5% | -148.3% |
| EPS | -0.28 | -0.63 | -0.92 | -0.55 |
| % Growth | 55.6% | 31.5% | -67.3% | – |
| EPS Diluted | -0.28 | -0.63 | -0.92 | -0.55 |
| Weighted Avg Shares Out | 90 | 84 | 83 | 83 |
| Weighted Avg Shares Out Dil | 90 | 84 | 83 | 83 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $3 | $1 |
| Interest Expense | $2 | $2 | $2 | $0 |
| Depreciation & Amortization | $1 | $2 | $2 | $1 |
| EBITDA | -$22 | -$49 | -$72 | -$33 |
| % Margin | -291.6% | -1,380.1% | -1,544.8% | -107.8% |